Literature DB >> 6370770

How does glucose regulate the human pancreatic A cell in vivo?

C M Asplin, P M Hollander, J P Palmer.   

Abstract

To investigate the mechanism whereby changes in plasma glucose level alter human pancreatic A-cell activity in vivo, A-cell activity was determined during manipulation of plasma glucose and pancreatic B-cell activity by insulin and glucose infusions. A-cell activity (the acute immunoreactive glucagon response to intravenous arginine, 0-10 min) rose from 482 +/- 125 to 968 +/- 191 pg X ml-1 X 10 min-1 (mean +/- SEM) when the plasma C-peptide level (a measure of B-cell activity) was suppressed from 2164 +/- 365 to 872 +/- 162 pg/ml by an insulin infusion at euglycaemia (employing the glucose clamp technique) in six normal subjects. Raising plasma glucose to 6.7 mmol/l during the same insulin infusion returned mean C-peptide (2688 +/- 581 pg/ml) and the acute glucagon response to arginine (447 +/- 146 pg X ml-1 X 10 min-1) close to basal levels. Individual changes in the acute glucagon response to arginine followed the C-peptide changes. The mean change in the acute glucagon response to arginine per unit change in plasma glucose (-191 +/- 36) was similar to that seen when plasma glucose was raised to twice basal levels in six different subjects without an insulin infusion (-159 +/- 45). This suggests that, when plasma glucose is raised to about twice basal level in vivo, the major factor in suppressing A-cell activity is the concurrent change in B-cell activity rather than direct effects of glucose or circulating insulin on the A cell.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370770     DOI: 10.1007/bf00252408

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  12 in total

1.  Letter: Carrier solutions for low-level intravenous insulin infusion.

Authors: 
Journal:  Br Med J       Date:  1976-01-17

2.  Effects of arterial versus venous sampling on analysis of glucose kinetics in man.

Authors:  E A McGuire; J H Helderman; J D Tobin; R Andres; M Berman
Journal:  J Appl Physiol       Date:  1976-10       Impact factor: 3.531

3.  Glucagon immunoassay using polyethylene glycol to precipitate antibody-bound hormone.

Authors:  J C Henquin; P Malvaux; A E Lambert
Journal:  Diabetologia       Date:  1974-02       Impact factor: 10.122

4.  Absence of islet alpha cell function in pancreatectomized patients.

Authors:  A Tiengo; M Bessioud; I Valverde; A Tabbi-Anneni; S Delprato; J Alexandre; R Assan
Journal:  Diabetologia       Date:  1982-01       Impact factor: 10.122

5.  Functional subdivision of islets of Langerhans and possible role of D cells.

Authors:  L Orci; R H Unger
Journal:  Lancet       Date:  1975-12-20       Impact factor: 79.321

6.  Production of antisera to synthetic benzyloxycarbonyl-C-peptide of human proinsulin.

Authors:  O K Faber; J Markussen; V K Naithani; C Binder
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1976-06

Review 7.  Role of glucagon in the pathogenesis of diabetes: the status of the controversy.

Authors:  R H Unger
Journal:  Metabolism       Date:  1978-11       Impact factor: 8.694

8.  Glucose clamp technique: a method for quantifying insulin secretion and resistance.

Authors:  R A DeFronzo; J D Tobin; R Andres
Journal:  Am J Physiol       Date:  1979-09

9.  Glucose regulation of glucagon secretion independent of B cell activity.

Authors:  C Asplin; P Raghu; T Dornan; J P Palmer
Journal:  Metabolism       Date:  1983-03       Impact factor: 8.694

10.  Glucose modulation of insulin and glucagon secretion in nondiabetic and diabetic man.

Authors:  P M Hollander; C M Asplin; J P Palmer
Journal:  Diabetes       Date:  1982-06       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.